These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice. Patoulias D; Manafis A; Mitas C; Avranas K; Lales G; Zografou I; Sambanis C; Karagiannis A Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):139-146. PubMed ID: 29412120 [TBL] [Abstract][Full Text] [Related]
26. Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report. Fukuda M; Nabeta M; Muta T; Fukami K; Takasu O Int J Emerg Med; 2020 Jan; 13(1):2. PubMed ID: 31969112 [TBL] [Abstract][Full Text] [Related]
27. Euglycemic Diabetic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor Use Post-Bariatric Surgery: A Brief Review of the Literature. Iqbal QZ; Mishiyev D; Zia Z; Ruggiero RA; Aftab G Cureus; 2020 Oct; 12(10):e10878. PubMed ID: 33178530 [TBL] [Abstract][Full Text] [Related]
28. Late-Onset Euglycemic Diabetic Ketoacidosis in a Patient With Massive Stroke Requiring Decompressive Craniectomy: A Case Report. Hussaini SA; Aziz A; Musa M; Alamin M; Danjuma M Cureus; 2021 Oct; 13(10):e18629. PubMed ID: 34765377 [TBL] [Abstract][Full Text] [Related]
29. Euglycemic Diabetic Ketoacidosis Precipitated by SGLT-2 Inhibitor Use, Pericarditis, and Fasting: A Case Report. Mendelsohn RA; Taveras AN; Mazer BA; Clayton LM Clin Pract Cases Emerg Med; 2020 Aug; 4(3):389-392. PubMed ID: 32926693 [TBL] [Abstract][Full Text] [Related]
30. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study. Rizvi SM; Shakil S; Biswas D; Shakil S; Shaikh S; Bagga P; Kamal MA CNS Neurol Disord Drug Targets; 2014 Apr; 13(3):447-51. PubMed ID: 24059302 [TBL] [Abstract][Full Text] [Related]
31. Post-surgical Euglycemic Diabetic Ketoacidosis in a Patient on Empagliflozin in the Intensive Care Unit. Bteich F; Daher G; Kapoor A; Charbek E; Kamel G Cureus; 2019 Apr; 11(4):e4496. PubMed ID: 31259114 [TBL] [Abstract][Full Text] [Related]
33. Post-Operative Euglycemic Diabetic Ketoacidosis in a Patient With SGLT-2 Inhibitor Use and Recent Sleeve Gastrectomy. Smith A; Holtrop J; Sadoun M Cureus; 2021 Apr; 13(4):e14297. PubMed ID: 33968511 [TBL] [Abstract][Full Text] [Related]
34. Sodium-Glucose Linked Transporter Inhibitors as a Cause of Euglycemic Diabetic Ketoacidosis on a Background of Starvation. Tauseef A; Asghar MS; Zafar M; Lateef N; Thirumalareddy J Cureus; 2020 Aug; 12(8):e10078. PubMed ID: 33005504 [TBL] [Abstract][Full Text] [Related]
35. Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy. Pace DJ; Dukleska K; Phillips S; Gleason V; Yeo CJ J Pancreat Cancer; 2018; 4(1):95-99. PubMed ID: 30631862 [No Abstract] [Full Text] [Related]
36. Prolonged diabetic ketoacidosis associated with canagliflozin. Sloan G; Kakoudaki T; Ranjan N Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29899991 [TBL] [Abstract][Full Text] [Related]
37. Euglycemic Diabetic Ketoacidosis in Pregnancy: A Case Report and Review of Current Literature. Jaber JF; Standley M; Reddy R Case Rep Crit Care; 2019; 2019():8769714. PubMed ID: 31531246 [TBL] [Abstract][Full Text] [Related]
38. Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature. Turner J; Begum T; Smalligan RD J Investig Med High Impact Case Rep; 2016; 4(3):2324709616663231. PubMed ID: 27635409 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Henry RR; Thakkar P; Tong C; Polidori D; Alba M Diabetes Care; 2015 Dec; 38(12):2258-65. PubMed ID: 26486192 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]